EDG 7500
Alternative Names: EDG-7500Latest Information Update: 22 Jun 2026
At a glance
- Originator Edgewise Therapeutics
- Class Cardiovascular therapies; Heart failure therapies; Small molecules; Urologics
- Mechanism of Action Sarcomere modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hypertrophic cardiomyopathy
- Phase I Kidney disorders
- Preclinical Cardiovascular disorders
Most Recent Events
- 16 Jun 2026 Updated efficacy and adverse events data from a phase II CIRRUS-HCM in Hypertrophic cardiomyopathy released by Edgewise Therapeutics
- 01 Jun 2026 Edgewise Therapeutics completes a phase I pharmacokinetics trial (In volunteers) in USA (PO) (NCT07456059)
- 07 Apr 2026 Edgewise Therapeutics completes a phase I pharmacokinetics trial (In volunteers) in USA (PO) (NCT07324616)